Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
Could RO7851624, newly into clinical trials, be RG6735?
Ideaya discontinues IDE275 and IDE705, previously ditched by GSK.
No sooner does one gammadelta-focused biotech die than another takes its place.
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
